Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 8, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the second quarter ended June 30, 2019 and provided a business update. “As we move toward reporting more mature interim overall survival (OS) results from our TIVO-3 study of tivozanib in advanced kidney cancer, AVEO continues to make meaningful clinical, regulatory and strategic progress across our pipeline,”
Category: Press Release
Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology
Download PDF TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 1, 2019– Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) and AVEO Oncology (NASDAQ: AVEO) announce that they have amended their license agreement to allow Kyowa Kirin to buy back the non-oncology rights of tivozanib in AVEO territories, which includes the U.S. and EU. The agreement is an amendment to the terms of the 2006 tivozanib license agreement
AVEO Oncology to Present at the 2019 BIO International Convention
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 29, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that Mike Ferraresso, Senior Vice President, Business Analytics and Commercial Operations, will present at the 2019 BIO International Convention in Philadelphia on Wednesday, June 5, 2019 at 4:30 p.m. EDT. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the
AVEO Oncology Announces Presentations at the 2019 ASCO Annual Meeting
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 15, 2019– AVEO Oncology (NASDAQ: AVEO) today announced two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting being held May 31-June 4, 2019 in Chicago, Illinois. Presentation Details Title: Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancerFirst Author: Wendy M. Swetzig, PhD, Northwestern University Feinberg School of MedicineAbstract Number: 5538Poster
AVEO Reports First Quarter 2019 Financial Results and Provides Business Update
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 9, 2019– AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2019 and provided a business update. “With a successful recent equity offering, together with the triggering of a FOTIVDA® (tivozanib) milestone from EUSA, AVEO’s strengthened balance sheet provides us with a cash runway that we expect will take us
AVEO Oncology to Participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 1, 2019– AVEO Oncology (NASDAQ:AVEO) today announced that members of the management team will participate in the 5th Annual SunTrust Robinson Humphrey Life Sciences Summit on Wednesday, May 8, 2019. The conference is being held May 7-8 in New York. About AVEO AVEO Pharmaceuticals, Inc. (the “Company” or “AVEO”) is a biopharmaceutical company seeking to advance targeted medicines
AVEO Oncology Announces $2M Milestone Payment From EUSA Pharma Related To Commercialization of FOTIVDA® in Spain
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 23, 2019– AVEO Oncology (NASDAQ:AVEO) today announced the triggering of a $2 million milestone payment to AVEO from EUSA Pharma. The milestone payment relates to the reimbursement approval and commercial launch in Spain of FOTIVDA® (tivozanib) as a first line treatment of adult patients with advanced renal cell carcinoma (RCC). Commercial launch in Spain is the third of five EU5 country
AVEO Pharmaceuticals, Inc. Announces Proposed Public Offering
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 3, 2019– AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced it has commenced an underwritten public offering of its shares of common stock, together with warrants to purchase shares of common stock. The Company intends
AVEO Pharmaceuticals, Inc. Announces Pricing of $25 Million Underwritten Public Offering
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–AVEO Pharmaceuticals, Inc. (Nasdaq: AVEO) (“AVEO” or the “Company”), a biopharmaceutical company seeking to advance targeted medicines for oncology and other unmet medical needs, today announced the pricing of its previously announced underwritten public offering of 21,739,131 shares of common stock and short-term warrants to purchase up to 21,739,131 shares of
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
Download PDF CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 2, 2019– AVEO Oncology (NASDAQ: AVEO) today announced that Michael Bailey, president and chief executive officer, will present at the H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019 at 2:10 p.m. BST. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the webcast